Page 27 - Breakthrough Device News Today

Except for statements of historical fact, certain information described in this Form 10-Q report contains forward-looking statements that involve substantial risks and uncertainties. You can identify... | May 10, 2022

U.S. Food and Drug Administration is permitting marketing for the first in vitro diagnostic test for early detection of amyloid plaques associated with Alzheimer’s disease.

The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation MedRhythms to receive a $3 million upfront payment... | May 5, 2022

The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)MedRhythms to receive a $3 million upfront payment as

The US Food and Drug Administration has cleared the first in vitro diagnostic test for early detection of Alzheimers disease.

RICHMOND, Calif.--(BUSINESS WIRE)--X-Therma Inc., a biotechnology company developing breakthrough technology for regenerative medicine and organ preservation - announced today that The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has granted its proprietary organ preser...

/PRNewswire/ -- Diadem SpA, a company developing the first blood-based test for the early prediction of progression to Alzheimers disease (AD), today...

/PRNewswire/ -- Diadem SpA, a company developing the first blood-based test for the early prediction of progression to Alzheimers disease (AD), today...

Diadem Announces Publication of Peer-Reviewed Article Describing How Post-Translational Modifications of p53 Variants May Contribute to Development of Alzheimer's Disease - read this article along with other careers information, tips and advice on BioSpace

Latest updates on this topic.